vs
Orthofix Medical Inc.（OFIX）与null（SDHC）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是Orthofix Medical Inc.的1.2倍（$260.4M vs $219.9M），null净利率更高（1.4% vs -1.0%，领先2.4%），Orthofix Medical Inc.同比增速更快（2.0% vs -9.4%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $8.7M），过去两年null的营收复合增速更高（17.3% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
史密斯韦森品牌公司是美国的枪械制造商，总部位于美国田纳西州玛丽维尔，是该领域历史悠久且知名的生产企业，在民用及警用枪械市场拥有较高的认可度。
OFIX vs SDHC — 直观对比
营收规模更大
SDHC
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出11.4%
-9.4%
净利率更高
SDHC
高出2.4%
-1.0%
自由现金流更多
OFIX
多$8.1M
$8.7M
两年增速更快
SDHC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $260.4M |
| 净利润 | $-2.2M | $3.5M |
| 毛利率 | 71.1% | 19.9% |
| 营业利润率 | 0.2% | 6.5% |
| 净利率 | -1.0% | 1.4% |
| 营收同比 | 2.0% | -9.4% |
| 净利润同比 | 92.4% | -14.3% |
| 每股收益（稀释后） | $-0.05 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSDHC
| Q4 25 | $219.9M | $260.4M | ||
| Q3 25 | $205.6M | $262.0M | ||
| Q2 25 | $203.1M | $223.9M | ||
| Q1 25 | $193.6M | $224.7M | ||
| Q4 24 | $215.7M | $287.5M | ||
| Q3 24 | $196.6M | $277.8M | ||
| Q2 24 | $198.6M | $220.9M | ||
| Q1 24 | $188.6M | $189.2M |
净利润OFIXSDHC
| Q4 25 | $-2.2M | $3.5M | ||
| Q3 25 | $-22.8M | $2.1M | ||
| Q2 25 | $-14.1M | $2.4M | ||
| Q1 25 | $-53.1M | $2.7M | ||
| Q4 24 | $-29.1M | $4.1M | ||
| Q3 24 | $-27.4M | $5.3M | ||
| Q2 24 | $-33.4M | $3.6M | ||
| Q1 24 | $-36.0M | $3.0M |
毛利率OFIXSDHC
| Q4 25 | 71.1% | 19.9% | ||
| Q3 25 | 72.2% | 21.0% | ||
| Q2 25 | 68.7% | 23.2% | ||
| Q1 25 | 62.8% | 23.8% | ||
| Q4 24 | 69.0% | 25.5% | ||
| Q3 24 | 68.7% | 26.5% | ||
| Q2 24 | 67.8% | 26.7% | ||
| Q1 24 | 67.5% | 26.1% |
营业利润率OFIXSDHC
| Q4 25 | 0.2% | 6.5% | ||
| Q3 25 | -8.3% | 6.6% | ||
| Q2 25 | -7.9% | 7.7% | ||
| Q1 25 | -25.2% | 8.7% | ||
| Q4 24 | -5.3% | 10.4% | ||
| Q3 24 | -9.6% | 14.2% | ||
| Q2 24 | -12.5% | 11.7% | ||
| Q1 24 | -15.6% | 11.3% |
净利率OFIXSDHC
| Q4 25 | -1.0% | 1.4% | ||
| Q3 25 | -11.1% | 0.8% | ||
| Q2 25 | -6.9% | 1.1% | ||
| Q1 25 | -27.4% | 1.2% | ||
| Q4 24 | -13.5% | 1.4% | ||
| Q3 24 | -13.9% | 1.9% | ||
| Q2 24 | -16.8% | 1.7% | ||
| Q1 24 | -19.1% | 1.6% |
每股收益（稀释后）OFIXSDHC
| Q4 25 | $-0.05 | $0.39 | ||
| Q3 25 | $-0.57 | $0.24 | ||
| Q2 25 | $-0.36 | $0.26 | ||
| Q1 25 | $-1.35 | $0.30 | ||
| Q4 24 | $-0.76 | $0.50 | ||
| Q3 24 | $-0.71 | $0.58 | ||
| Q2 24 | $-0.88 | $0.40 | ||
| Q1 24 | $-0.95 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $12.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $86.7M |
| 总资产 | $850.6M | $557.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXSDHC
| Q4 25 | $82.0M | $12.7M | ||
| Q3 25 | $62.9M | $14.8M | ||
| Q2 25 | $65.6M | $16.8M | ||
| Q1 25 | $58.0M | $12.7M | ||
| Q4 24 | $83.2M | $22.4M | ||
| Q3 24 | $30.1M | $23.7M | ||
| Q2 24 | $26.4M | $17.3M | ||
| Q1 24 | $27.0M | $32.8M |
总债务OFIXSDHC
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXSDHC
| Q4 25 | $450.0M | $86.7M | ||
| Q3 25 | $442.5M | $82.2M | ||
| Q2 25 | $458.3M | $80.0M | ||
| Q1 25 | $458.3M | $76.9M | ||
| Q4 24 | $503.1M | $73.6M | ||
| Q3 24 | $525.9M | $68.4M | ||
| Q2 24 | $546.0M | $62.1M | ||
| Q1 24 | $570.3M | $59.7M |
总资产OFIXSDHC
| Q4 25 | $850.6M | $557.6M | ||
| Q3 25 | $832.6M | $571.6M | ||
| Q2 25 | $837.2M | $570.2M | ||
| Q1 25 | $823.1M | $513.9M | ||
| Q4 24 | $893.3M | $475.9M | ||
| Q3 24 | $867.9M | $460.1M | ||
| Q2 24 | $882.0M | $429.3M | ||
| Q1 24 | $906.0M | $401.3M |
负债/权益比OFIXSDHC
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $9.8M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $8.7M |
| 自由现金流率自由现金流/营收 | 7.6% | 3.4% |
| 资本支出强度资本支出/营收 | 4.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 2.77× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-36.9M |
8季度趋势，按日历期对齐
经营现金流OFIXSDHC
| Q4 25 | $27.7M | $9.8M | ||
| Q3 25 | $12.4M | $22.8M | ||
| Q2 25 | $11.6M | $-28.9M | ||
| Q1 25 | $-18.4M | $-34.9M | ||
| Q4 24 | $23.7M | $5.5M | ||
| Q3 24 | $11.7M | $22.9M | ||
| Q2 24 | $9.0M | $39.0K | ||
| Q1 24 | $-18.6M | $-9.3M |
自由现金流OFIXSDHC
| Q4 25 | $16.8M | $8.7M | ||
| Q3 25 | $2.5M | $21.4M | ||
| Q2 25 | $4.5M | $-31.1M | ||
| Q1 25 | $-25.1M | $-35.9M | ||
| Q4 24 | $15.2M | $4.8M | ||
| Q3 24 | $6.3M | $22.3M | ||
| Q2 24 | $-360.0K | $-2.1M | ||
| Q1 24 | $-29.1M | $-9.7M |
自由现金流率OFIXSDHC
| Q4 25 | 7.6% | 3.4% | ||
| Q3 25 | 1.2% | 8.2% | ||
| Q2 25 | 2.2% | -13.9% | ||
| Q1 25 | -13.0% | -16.0% | ||
| Q4 24 | 7.0% | 1.7% | ||
| Q3 24 | 3.2% | 8.0% | ||
| Q2 24 | -0.2% | -1.0% | ||
| Q1 24 | -15.4% | -5.1% |
资本支出强度OFIXSDHC
| Q4 25 | 4.9% | 0.4% | ||
| Q3 25 | 4.8% | 0.5% | ||
| Q2 25 | 3.5% | 0.9% | ||
| Q1 25 | 3.5% | 0.5% | ||
| Q4 24 | 4.0% | 0.2% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 4.7% | 1.0% | ||
| Q1 24 | 5.6% | 0.2% |
现金转化率OFIXSDHC
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | 10.70× | ||
| Q2 25 | — | -12.24× | ||
| Q1 25 | — | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | 4.28× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | -3.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
